Director
Merck and Co Inc
Rahway, New Jersey
Hanmi Xi has made significant scientific contributions in pharmaceutical sciences over her 20+ years in the field. Since joining Merck in 2009, she had directly supported >20 pipeline programs through different development stages and across multiple modalities including enabled oral dosage form, long acting parenteral and oral peptide either as functional area lead or CMC lead. Her research on spray-dried particles and high amorphous solid dispersion loading tablets has led to several patents and first-author publications. Hanmi's work on deep learning convolutional neural networks for internal tablet defect detection showcases her commitment to integrating advanced technologies in pharmaceutical development.
Since January 2020, Hanmi has led the biophysical characterization group as a director, focusing on building robust biophysical support for biological pipeline and advancing expertise in particle characterization and various biophysical tools. Under her oversight, her team has achieved notable advancements in understanding the effects of silicone oil and surfactants on the physical stability of therapeutic proteins and developing novel analytical tools for aggregation characterization.
Hanmi's dedication to scientific excellence is evident in her numerous publications in prestigious journals and her role as a mentor to the next generation of scientists. Her contributions continue to advance pharmaceutical sciences and inspire innovation.
Disclosure information not submitted.
Navigating Challenges of High Concentration Protein Therapeutics: Advanced Analytical Approaches
Tuesday, November 11, 2025
9:30 AM - 10:00 AM CT